IW 363

April 29, 2026 Viktor Zarev 0 min read
  1. FDA launches “real-time clinical trials” for faster drug review.
  2. GLP-1 drug improves motivation in trial with depressed patients.
  3. New survey tracks rise in health system CEO pay. 
  4. Congressional hearing criticizes CEOs for high healthcare costs.
  5. OxyContin maker Purdue to dissolve as criminal trial concludes.
  6. Utah medical board wants to suspend AI prescription program.
  7. Nebraska first to implement Medicaid work mandates next month,
  8. Health companies jockey for share of $50B rural health fund.
  9. FDA testing confirms safety of infant formula. 
  10. CDC says backyard poultrymay raise salmonella risk.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Pharmaceuticals May 7, 2026

Aficamten, ACACIA-HCM, and the Road to the First nHCM Drug May 7, 2026

The question of how to treat non-obstructive hypertrophic cardiomyopathy has long perplexed researchers and pharmaceutical developers alike, but topline results from Cytokinetics’ Phase 3 ACACIA-HCM trial suggest MYQORZO (aficamten) could be the answer.

Cardiovascular Disease May 4, 2026

The True Cause of Sudden Cardiac Death May 4, 2026

It’s not often that a pair of studies completely challenges our assumptions in cardiology, but new data presented at HRS 2026 suggests myocardial infarction might not be […]

Cardiology April 30, 2026

Cardiac Wire’s Top Six of HRS 2026 April 30, 2026

The Heart Rhythm Society's Annual Meeting for 2026 electrified Chicago with talks of the latest EP tech, rhythm management debates, and insights into where remote patient monitoring is headed. Here are Cardiac Wire’s top-six takeaways from electrophysiology’s biggest weekend of the year.